Log in to MyKarger to check if you already have access to this content.
Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price. Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more Select* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details AbstractPurpose: To evaluate the treatment outcomes of estrogen receptor-positive/human epidermal growth factor receptor 2-negative(ER+/HER2−) breast cancer according to the risk group using EndoPredict(EP) score. Patients and Methods: Between 2015 and 2019, 207 patients with ER+/HER2− pN0-N1 early breast cancer who underwent surgery, EP test, and adjuvant radiotherapy were accrued. EPclin score, which combines the molecular EP score with nodal status and tumor size, was calculated, and patients were divided into EPclin low- or high-risk groups by the cutoff value of 3.3. Results: There were 154 and 53 patients in the EPclin low- and high-risk groups, respectively. Forty-one patients(81.1%) of the high-risk group received adjuvant chemotherapy, while only 1(0.6%) of the low-risk group did. With a median follow up of 54.1 months(range 8.2−76.6), the 5-year disease-free survival rates of low- and high-risk groups were 100% and 88.9%, respectively(p
S. Karger AG, Basel
Article / Publication Details Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
留言 (0)